Details of the Drug

General Information of Drug (ID: DM84AVQ)

Drug Name

CY6463

Synonyms

Zagociguat; Zagociguat [INN]; H7KEN3O8AI; UNII-H7KEN3O8AI; 2201048-82-8; CY6463; 8-(2-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo(1,2-a)pyrazine; Imidazo(1,2-a)pyrazine, 8-((2-fluorophenyl)methyl)-6-(5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl)-; Imidazo[1,2-a]pyrazine, 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]-; ZAGOCIGUAT [USAN]; SCHEMBL19922804; GTKNNCQKFKGSHR-UHFFFAOYSA-N; EX-A7620; AKOS040757400; CY-6463; IW-6463; MS-25746; HY-145607; CS-0376702; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C16H10F4N6
Canonical SMILES: C1=CC=C(C(=C1)CC2=NC(=CN3C2=NC=C3)C4=NNC(=N4)C(F)(F)F)F
InChI: InChI=1S/C16H10F4N6/c17-10-4-2-1-3-9(10)7-11-14-21-5-6-26(14)8-12(22-11)13-23-15(25-24-13)16(18,19)20/h1-6,8H,7H2,(H,23,24,25)
InChIKey: GTKNNCQKFKGSHR-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 134304734
UNII: H7KEN3O8AI
DrugBank ID: DB18315
TTD ID: DO37EF

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Soluble guanylate cyclase (GCS)	TT23PYC	GCYA1_HUMAN ; GCYB1_HUMAN	Stimulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04798989) A Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 When Administered to Participants With Alzheimer's Disease and Vascular Pathology. U.S.National Institutes of Health.
2	First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clin Transl Sci. 2023 Aug;16(8):1381-1395.